- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04798924
Visual Rehabilitation After Occipital Stroke
Study Overview
Status
Conditions
- Stroke, Ischemic
- Stroke Hemorrhagic
- Visual Field Defect, Peripheral
- Hemianopsia
- Hemianopia
- Quadrantanopia
- Homonymous Hemianopia
- Occipital Lobe Infarct
- Visual Fields Hemianopsia
- Vision Loss Partial
- Peripheral Visual Field Defect of Both Eyes
- Peripheral Visual Field Defect
- Homonymous Hemianopsia
- Quadrantanopsia
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Chrys Callan
- Phone Number: 585-276-3426
- Email: christine_callan@URMC.Rochester.edu
Study Locations
-
-
New York
-
Rochester, New York, United States, 14642
- Recruiting
- University of Rochester
-
Principal Investigator:
- Krystel Huxlin, PhD
-
Contact:
- Christine Callan
- Phone Number: 585-276-3426
- Email: christine_callan@urmc.rochester.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Residents of US and Canada
- MRI and/or CT scans showing evidence of one-sided / unilateral stroke or stroke-like damage to the primary visual cortex or its immediate afferent white matter sustained less than 6-months prior to enrollment
- Reliable visual field defects in both eyes as measured by Humphrey, Macular Integrity Assessment (MAIA), Goldmann, and/or equivalent perimetry. This deficit must be large enough to enclose a 5-deg diameter visual stimulus.
- Ability to fixate on visual targets reliably for 1000ms (as demonstrated by visual fields, and verified in study participation)
- Willing and safely able to undergo magnetic resonance imaging (MRI) scanning
- Willing, able, and competent to provide informed consent
- Fluent in written and spoken English
- Cognitively able, responsible, and willing to complete daily visual training independently at home for several months.
Exclusion Criteria:
- Past or present ocular disease interfering with vision
- Best corrected visual acuity worse than 20/40 in either eye
- Presence of damage to the dorsal Lateral Geniculate Nucleus, as shown on MRI/CT scans
- Diffuse, whole brain degenerative processes
- Brain damage deemed by study staff to potentially interfere with training ability or outcome measures
- History of traumatic brain injury
- Documented history of drug/alcohol abuse
- Currently use of neuroactive medications which would impact training, as determined by PI
- Cognitive or seizure disorders
- One-sided attentional neglect
- Inability to perform the visual training exercises as directed
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Training in the blind field
Training in the blind field using specialized software
|
A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home.
They will perform one to two daily training sessions in their home, consisting of 200-300 trials each.
The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the blind field.
The computer program will automatically create a record of patient performance during each home training session.
Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least one and up to 6 months.
After the initial training period of one to six months, the same computer software will continue to be used for all subjects.
The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the blind field.
The computer program will automatically create a record of patient performance during each home training session.
Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least 6 months.
|
Experimental: Training in the intact field
Training in the intact field using specialized software
|
After the initial training period of one to six months, the same computer software will continue to be used for all subjects.
The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the blind field.
The computer program will automatically create a record of patient performance during each home training session.
Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least 6 months.
A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home.
They will perform one to two daily training sessions in their home, consisting of 200-300 trials each.
The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the intact field.
The computer program will automatically create a record of patient performance during each home training session.
Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least one and up to 6 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Direction Discrimination Threshold
Time Frame: baseline, 6 months, 12 months
|
For each subject, we will measure the ability to detect differences in the motion direction of visual stimuli relative to horizontal, measured in degrees of visual angle. These assessments will be based on what can be reliably detected at a 72-75% correct level of performance. These measures of change will be evaluated baseline to 6-months post-stroke, then 6- to 12-months post stroke, and baseline to 12-months.** **NOTE: Our protocol allows for a +1 month variance for all timepoints. |
baseline, 6 months, 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Direction Integration Threshold
Time Frame: baseline, 6 months, 12 months
|
This will measure the ability of subjects to integrate across a range of motion directions measured in degrees of visual angle. These assessments will be based on what range of motion directions can be reliably integrated at a 72-75% correct level of performance. These measures of change will be evaluated baseline to 6-months post-stroke, then 6- to 12-months post stroke, and baseline to 12-months. **NOTE: Our protocol allows for a +1 month variance for all timepoints. |
baseline, 6 months, 12 months
|
Contrast Sensitivity for Direction
Time Frame: baseline, 6 months, 12 months
|
Assessment of visual perception transfer to untrained psychophysical tasks of contrast sensitivity for direction discrimination. For each subject, we will measure the ability to correctly detect the motion direction of visual stimuli that are also varying in contrast against a grey background. We will measure the luminance contrast that can be reliably detected at a 72-75% correct level of performance. These measures of change will be evaluated baseline to 6-months post-stroke, then 6- to 12-months post stroke, and baseline to 12-months. **NOTE: Our protocol allows for a +1 month variance for all timepoints. |
baseline, 6 months, 12 months
|
contrast sensitivity for static orientation
Time Frame: baseline, 6 months, 12 months
|
Assessment of visual perception transfer to untrained psychophysical tasks of contrast sensitivity for static orientation discrimination. For each subject, we will measure the ability to correctly detect the orientation of non-moving visual stimuli that vary in contrast against a grey background. We will measure the luminance that can be reliably detected at a 72-75% correct level of performance. These measures of change will be evaluated baseline to 6-months post-stroke, then 6- to 12-months post stroke, and baseline to 12-months. **NOTE: Our protocol allows for a +1 month variance for all timepoints. |
baseline, 6 months, 12 months
|
Ganglion cell complex thickness laterality
Time Frame: baseline, 6 months, 12 months
|
Change in thickness of the ganglion cell complex will be measured by retinal optical coherence tomography (OCT) scans from baseline to 6- and 12- months post stroke.** We will perform OCT imaging of the foveal region of the retina (6mm ETDRS) in both eyes of each patient. Images will be automatically segmented. Estimated thickness of the ganglion cell complex will be extracted and aligned with estimates of the blind field's visual sensitivity obtained from fundus-controlled MAIA perimetry. We will then compute a laterality index LI as follows: LIGCCT=(Tc-Ti)/(Tc+Ti) where Tc=thickness in the control lateral OCT quadrant, Ti=thickness in the impaired lateral OCT quadrant. **NOTE: Our protocol allows for a +1 month variance for all timepoints. |
baseline, 6 months, 12 months
|
Ganglion cell complex volume laterality
Time Frame: baseline, 6 months, 12 months
|
Change in volume of the ganglion cell complex will be measured by retinal optical coherence tomography (OCT) scans from baseline to 6- and 12- months post stroke.** We will perform OCT imaging of the foveal region of the retina (6mm ETDRS) in both eyes of each patient. Images will be automatically segmented. Estimated volume of the ganglion cell complex will be extracted and aligned with estimates of the blind field's visual sensitivity obtained from fundus-controlled MAIA perimetry. We will then compute a laterality index as follows: LIGCCT=(Tc-Ti)/(Tc+Ti) where Tc=thickness in the control lateral OCT quadrant, Ti=thickness in the impaired lateral OCT quadrant. **NOTE: Our protocol allows for a +1 month variance for all timepoints. |
baseline, 6 months, 12 months
|
Optic Tract (OT) laterality
Time Frame: baseline, 6 months, 12 months
|
OT volume analysis will be performed from high resolution structural T1 MRI images of the brain.
Mirrored masks of equal size will be hand-drawn over the OTs in each brain slice of a given subject, starting three slices posterior to the optic chiasm and continuing posteriorly until the OTs are no longer distinct from surrounding structures.
The volume of each optic tract will be calculated from these masks by first establishing the maximum voxel intensity (range from 0 to 255) across the two OTs, then counting the number of voxels in each OT mask with brightness values between 5 and 85% of this maximum.
We will then compute an OT laterality Index (LI85) to represent the relative difference in estimated volume between the two OTs of each participant, where LI85=(OTc-OTi)/(OTc+OTi), where OTc=number of voxels with brightness 5-85% of maximum in the contralesional OT and OTi = number of voxels with brightness 5-85% of maximum in the ipsilesional OT.
|
baseline, 6 months, 12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MAIA Visual Field Perimetry
Time Frame: baseline, 6 months, 12 months
|
We will measure the change in visual sensitivity (measured in decibels) at all locations tested by the system. These changes will be measured and compared between baseline, 6-months post stroke, and 12 months post stroke.** **NOTE: Our protocol allows for a +1 month variance for all timepoints. |
baseline, 6 months, 12 months
|
Humphrey 10-2 and 24-2 perimetry
Time Frame: baseline, 6 months, 12 months
|
We will measure the change in visual sensitivity (measured in decibels) at all locations tested by the system. These changes will be measured and compared between baseline, 6-months post stroke, and 12 months post stroke.** **NOTE: Our protocol allows for a +1 month variance for all timepoints. |
baseline, 6 months, 12 months
|
Goldmann perimetry
Time Frame: baseline, 6 months, 12 months
|
We will measure the change in area of vision (degrees squared) as encompassed by each isopter, measured by one of 3 different light stimuli. The 3 isopters we will compare are:
These changes will be measured and compared between baseline, 6-months post stroke, and 12 months post stroke.** **NOTE: Our protocol allows for a +1 month variance for all timepoints. |
baseline, 6 months, 12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 00005966
- 3R01EY027314-06S2 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke, Ischemic
-
Nordsjaellands HospitalRigshospitalet, Denmark; Metropolitan University CollegeCompletedTransient Ischemic Attack | Stroke, Ischemic | Stroke HemorrhagicDenmark
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
Medtronic Cardiac Rhythm and Heart FailureMedtronic Bakken Research CenterCompletedCryptogenic Symptomatic Transient Ischemic Attack | Cryptogenic Ischemic StrokeNetherlands, United States, France, Belgium, Germany, Sweden, Italy, Austria, Canada, Denmark, Finland, Greece, Slovakia, Spain
-
University Hospital, BrestCompletedStroke, Ischemic | Stroke HemorrhagicFrance
-
Sheffield Teaching Hospitals NHS Foundation TrustUnknownFatigue | Stroke, Ischemic | Stroke HemorrhagicUnited Kingdom
-
Umbria Bioengineering TechnologiesRecruitingStroke, Ischemic | Stroke HemorrhagicItaly
-
BayerRecruitingAcute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic AttackUnited States, Switzerland, Belgium, Australia, Sweden, Canada, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, China, Greece, Japan, Turkey, Netherlands, Romania, United Kingdom, Portugal, Hungary, Italy, Brazil, France, S... and more
-
University of AlbertaCompletedTransient Ischemic Attack | Minor Ischemic StrokeCanada
-
Stephanie HarrisonActive, not recruitingTransient Ischemic Attack | Stroke, IschemicUnited Kingdom
Clinical Trials on Subacute Training in the blind field
-
University of RochesterNational Eye Institute (NEI)Active, not recruitingStroke, Ischemic | Hemianopia | Quadrantanopia | Vision Loss Partial | Hemianopia HomonymousUnited States
-
University of RochesterEnvision Solutions, LLCCompletedHemianopia | Quadrantanopia | Stroke Induced Vision LossUnited States
-
University of RochesterNot yet recruitingStroke, Ischemic | Hemianopia | Quadrantanopia | Cortical Blindness | Vision Loss Partial | Hemianopia Homonymous | Vision; Loss, Both Eyes | Stroke - Occipital InfarctionUnited States
-
University of OxfordUniversity of Rochester; University of Turin, Italy; University of Texas at AustinRecruitingHemianopsia | Hemianopia | Quadrantanopia | Stroke Induced Vision LossUnited Kingdom
-
Fondation Ophtalmologique Adolphe de RothschildTerminated
-
Medipol UniversityNot yet recruiting
-
University of VirginiaCompleted
-
Kubota Vision Inc.Completed
-
Manchester Metropolitan UniversityEuropean Society for Clinical Nutrition and MetabolismRecruitingCardiovascular Diseases | Obesity | Diabetes Mellitus, Type 2United Kingdom
-
National Institute of Cardiology, Laranjeiras,...WithdrawnObesity | Overweight | Physical ActivityBrazil